Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Troy Budd"'
Autor:
Michael E. Roth, Joseph M. Unger, Ann M. O'Mara, Mark A. Lewis, Troy Budd, Rebecca H. Johnson, Brad H. Pollock, Charles Blanke, David R. Freyer
Publikováno v:
Cancer Medicine, Vol 9, Iss 6, Pp 2146-2152 (2020)
Abstract Background Few adolescents and young adults (AYAs, 15‐39 years old) enroll onto cancer clinical trials, which hinders research otherwise having the potential to improve outcomes in this unique population. Prior studies have reported that A
Externí odkaz:
https://doaj.org/article/55acfd57bc5d44f6a4fefa5aa18677b3
Autor:
Rebecca H. Johnson, Brad H. Pollock, Joseph M. Unger, Ann M. O'Mara, Mark A. Lewis, David R. Freyer, Michael Roth, Troy Budd, Charles D. Blanke
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 6, Pp 2146-2152 (2020)
Cancer medicine, vol 9, iss 6
Cancer Medicine, Vol 9, Iss 6, Pp 2146-2152 (2020)
Cancer medicine, vol 9, iss 6
Background Few adolescents and young adults (AYAs, 15‐39 years old) enroll onto cancer clinical trials, which hinders research otherwise having the potential to improve outcomes in this unique population. Prior studies have reported that AYAs are m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7095dd32314bdd1a667e01bf2987b1
http://europepmc.org/articles/PMC7064039
http://europepmc.org/articles/PMC7064039
Autor:
Michael E. Roth, Joseph M. Unger, Ann M. O'Mara, Mark A. Lewis, Troy Budd, Rebecca H. Johnson, Brad H. Pollock, Charles Blanke, David R. Freyer
The cover image is based on the Original Research Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era by Michael E. Roth et al., https://doi.org/10.1002/cam4.2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aac60e89e01761fe60cadcf182498ca
https://europepmc.org/articles/PMC7064024/
https://europepmc.org/articles/PMC7064024/
Publikováno v:
Journal of Clinical Oncology. 37:e14587-e14587
e14587 Background: Despite the identification of multiple patient, clinician, and health systems barriers, accrual to a new generation of cancer clinical trials continues to present challenges. It may be that barrier data is not sufficiently granular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb489f3e153e7e4eeecb1d28e6aa87f
https://doi.org/10.1200/jco.2019.37.15_suppl.e14587
https://doi.org/10.1200/jco.2019.37.15_suppl.e14587
Publikováno v:
Pediatric Blood & Cancer. 50:1101-1104
In the United States, Europe, and Australia, and probably all countries of the world, older adolescents and young adults with cancer are under-represented in clinical trials of therapies that could improve their outcome. Simultaneously, the survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1df0a704cd25d1da4ecb9a523401a37
https://doi.org/10.1002/pbc.21459
https://doi.org/10.1002/pbc.21459
Publikováno v:
Cancer. 103:1891-1897
BACKGROUND Young adults with cancer in the U.S. have had less improvement in survival than either younger patients or older patients. The authors attempted to determine whether similar deficits have occurred in young adults with sarcomas and, if so,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d94a81b4d6ab7cdcda9a0183e91218be
https://doi.org/10.1002/cncr.20995
https://doi.org/10.1002/cncr.20995
Publikováno v:
Cancer and the Adolescent, Second Edition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb153a5ef908003445227539d10f77f
https://doi.org/10.1002/9780470994733.ch3
https://doi.org/10.1002/9780470994733.ch3
Publikováno v:
Cancer. 107
In the U.S., older adolescents and young adults with cancer have benefited less from therapeutic advances than did either younger or older patients. One factor that may explain this deficit is the relative lack of participation of patients in this ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::075f085482441e95a08e3881d41c938f
https://pubmed.ncbi.nlm.nih.gov/16906507
https://pubmed.ncbi.nlm.nih.gov/16906507
Autor:
Troy Budd, Elizabeth Horstmann, Mary S. McCabe, Ezekiel J. Emanuel, D. Dale Shoemaker, Christine Grady, Seiichiro Yamamoto, Louise B. Grochow, Larry Rubinstein
Publikováno v:
The New England journal of medicine. 352(9)
Previous reviews of phase 1 oncology trials reported a rate of response to treatment of 4 to 6 percent and a toxicity-related death rate of 0.5 percent. These results may not reflect the rates in current phase 1 oncology trials.We reviewed all nonped
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daaab3d97deb4a74e5a6a562df26a70c
https://pubmed.ncbi.nlm.nih.gov/15948271
https://pubmed.ncbi.nlm.nih.gov/15948271
Autor:
Sally Hunsberger, Denise Riedel Lewis, Ann M. O'Mara, Nita L. Seibel, Troy Budd, David R. Freyer, Steven H. Friedman, Shanda Finnigan
Publikováno v:
Journal of Clinical Oncology. 32:10058-10058
10058 Background: Lack of participation in clinical trials has been proposed as a key explanation for the survival deficit of AYAO patients. We compared the proportion of newly diagnosed AYAO patie...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5836488417fec609cd3ceea25365187d
https://doi.org/10.1200/jco.2014.32.15_suppl.10058
https://doi.org/10.1200/jco.2014.32.15_suppl.10058